Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 29;9:689. doi: 10.3389/fonc.2019.00689

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Del Giudice, Raponi, Della Starza, De Propris, Cavalli, De Novi, Cappelli, Ilari, Cafforio, Guarini and Foà.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Percentages of undetectable MRD (uMRD) in peripheral blood (PB) and bone marrow (BM) compartments across different clinical trials. On the Left, the standard chemoimmunotherapy for CLL patients. On the Right, the most recent clinical trials incorporating BCR/BCL2 inhibitors. FCR, fludarabine+cyclophosphamide+rituximab (CLL8) (14, 81); R-Benda, rituximab+bendamustine (CLL10) (82); Chl+G, chlorambucil+obinutuzumab (CLL11) (83, 84); Benda+G, bendamustine+obinutuzumab (GREEN) (85); Ibr+R, ibrutinib+rituximab (Alliance A041202) (86); Benda+Ibr+Ofa, bendamustine+ibrutinib+ofatumumab (CLL2-BIO) (87); Ibr+G, ibrutinib+obinutuzumab (Illuminate PCYC-1130) (88); Benda+Ibr+G, bendamustine+ibrutinib+obinutuzumab (CLL2-BIG) (89); Ibr+FC+G, ibrutinib+fludarabine+cyclophosphamide+obinutuzumab (90); Ven+R (EOCT, End Of Combination Therapy) (EOT, End Of Therapy), venetoclax+rituximab (Murano) (23, 91); Benda+Ven+G, bendamustine+venetoclax+obinutuzumab (CLL2-BAG) (92); Ven+G, venetoclax+obinutuzumab (CLL14) (93); Ven+Ibr (+12 m, months), venetoclax+ibrutinib (TAP Clarity) (94); Ven+Ibr (+18 m, months), venetoclax+ibrutinib (95).